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A Comparison of Methods for Estimating the Causal Effect of a Treatment in Randomized
Clinical Trials Subject to Noncompliance
Roderick Little 1 , Qi Long2 and Xihong Lin 3

Abstract
We consider the analysis of clinical trials that involve randomization to an active treatment (T =
1) or a control treatment (T = 0), when the active treatment is subject to all-or- nothing
compliance. We compare three approaches to estimating treatment efficacy in this situation: astreated analysis, per-protocol analysis, and instrumental variable (IV) estimation, where the
treatment effect is estimated using the randomization indicator as an instrumental variable. Both
model-based and method-of-moment based IV estimators are considered. The assumptions
underlying these estimators are assessed, standard errors and mean squared errors of the
estimates are compared, and design implications of the three methods are examined. Extensions
of the methods to include observed covariates are then discussed, emphasizing the contrasting
role of covariates in these extensions. Methods are illustrated on data from the Women Take
Pride study, an assessment of behavioral treatments for women with heart disease.
Keywords: as-treated analysis, per-protocol analysis, causal inference, instrumental variables,
principal stratification, propensity scores.
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1. Introduction
Randomized clinical trials that compare treatments are straightforward to analyze when
all individuals in the study take the assigned treatment, and outcomes are reported without
missing data. The analysis and interpretation is complicated when individuals do not comply
with their assigned treatments. The gold-standard analysis of such trials in drug approval
processes is intention-to-treat (IT), where compliance information is ignored, and individuals are
classified in treatment comparisons according to their assigned treatments, regardless of whether
the treatment was taken. IT analysis preserves the benefits of randomized allocation of
treatments, and it provides valid measures of the effect of treatment assignment, which is
sometimes called treatment effectiveness. The analysis is less compelling for estimating the
effect of treatment efficacy, which concerns the pharmacological or behavioral effectiveness of a
treatment when it is in fact taken.
Simple approaches to estimating treatment efficacy are as treated (AT) analysis, which
compares average treatment effects with participants classified according the treatment actually
received, and per-protocol (PP) analysis, which compares the average treatment effects for
participants who comply with the assigned treatment. These analyses both classify participants
according to received treatment, and hence are direct measures of treatment efficacy, but they are
both subject to bias, in that participants who comply with a particular treatment may be a biased
sample of participants randomized to that treatment. The selection bias may be reduced by
adjustment for covariates, but it remains a concern. Thus current clinical tria l practice for
estimating efficacy involves an unappealing choice between IT analysis, which is protected from
bias by randomization but is really estimating effectiveness rather than efficacy, and PP and AT
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analysis, which are directly attempting to measure efficacy but are subject to bias since the
randomization is corrupted by treatment noncompliance.
Recent literature has advocated another approach to estimating efficacy, based on treating
the randomization as an instrumental variable (IV), in economic parlance. In simple terms the IV
estimator corrects the IT estimator for noncompliance, based on certain assumptions about the
outcomes for non-compliers under both treatments. This approach has the attraction of yielding a
direct estimate of treatment efficacy, and is also protected from selection bias by the
randomization. On the other hand, it does require certain assumptions to be valid, and it also
yields estimators with potentially high variance, particularly if the treatment compliance rate is
low. Model-based versions of the IV estimator have been proposed that are potentially more
efficient, although they make stronger distributional assumptio ns.
The first objective of this paper is to provide a side-by-side comparison of the PP, AT
and IV estimators of efficacy, which elucidates the assumptions made by the different methods
and discusses their relative efficiencies. Previous papers that advocate the IV estimator and
model-based enhancements essentially dismiss the PP and AT approaches because of their
potential bias, but the assumptions under which these methods are valid are rarely explicitly
articulated, and we think a direct side-by-side comparison of the methods is illuminating. We
attempt to make the comparison as transparent and non- mathematical as possible, by focusing on
the simplest non-trivial situation and avo iding unnecessarily algebraic formulations.
A second objective is to elucidate and compare the role of covariates in improving the
performance of the PP, AT and IV estimators. We show that covariates can reduce bias for PP
and AT estimation but not for IV estimation, and can improve precision for all the methods.
Finally we outline some extensions of these results to more general settings.
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Our analysis provides an instructive non-technical introduction to some important ideas
in causal inference, namely the definition of a causal effect of an active treatment as the
difference in hypothetical outcomes under that treatment and a control treatment (Rubin 1974,
1977, 1978), and the idea of principal stratification, where individuals are stratified according to
the values of the post-treatment variable under both treatments, rather than simply under the
treatment actually observed (Frangakis and Rubin, 2002).
2. The Women Take PRIDE Study
Data from the “Women take PRIDE” (WTP) heart disease management study (Janevic et
al., 2003) are used to illustrate our methods. In this study, participants are elder women with
heart disease and the intervention is a self- regulatory process for identifying and resolving
problems in managing their heart conditions (e.g., increasing physical activity). Two versions of
the intervention were administered: a Group format, where 6-8 women study the educational
material for 2-2.5 hours/week in a group setting; and a Self-Directed format, where each
participant studies the same content on an individual basis at home after attending an in-person
orientation session. The intervention program consists of 6 weekly classes for the Group format
and 6 weekly units for the Self-Directed format. Compliance is defined as attendance of at least
once Group class, or, equivalently, completion of at least one Self- Directed weekly unit.
This study adopted a doubly randomized preference trial (DRPT) (Long et al. 2006), with
both a completely randomized arm (n=575), where participants were randomized to Group
format, Self-Directed form and a control “usual care” format, and a choice arm (n-553) where
participants were allowed to choose their treatment. One of the objectives in the WTP study is to
assess efficacy of disease- management programs compared to the control format, accounting for
noncompliance. The outcomes of interest include indicators of physical, psychological, and
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functional health status, measured at baseline and months 4, 12, and 18. For more details on the
WTP study, see Janevic et al., 2003.
The purpose of this paper is to provide an in-depth comparison of the assumptions,
properties and relationship of the as-treated (AT), per-protocol (PP) and instrumental variable
(IV) estimators for treatment efficacy in trials involving an active treatment and a placebo. We
hence restrict our attention to the randomized arm, and compare subjects assigned to Group
format (T=1, n=190) with the control format (T=0, n=184). In particular, we choose the outcome
“6 minute walk” at Month 12, which measures the distance in feet an individual can walk in 6
minutes. Baseline 6- minute walk, and demographic characteristics at baseline, namely age and
employment status, are chosen as covariates for methods involving covariate adjustment.
3. The Problem
We consider the analysis of clinical trials that involve randomization to an active
treatment (T = 1) or a control treatment (T = 0), when the active treatment is subject to all-ornothing compliance (Baker 1997). It is assumed that compliance to the control treatment is
perfect, so noncompliance is only an issue when assigned the active treatment. The population
can then be divided into two groups: never-takers or non-compliers (C = 0), who take the control
treatment whether they are assigned to the control or active treatment, and compliers who take
the treatment they are assigned (C = 1). We call the variable C principal compliance, since it is a
special case of principal stratification, where subjects are classified by the values of a posttreatment variable (here compliance) under both treatments (Frangakis and Rubin 2002). Note
that principal compliance is not the same as observed compliance, which depends only on
whether a participant complied with the assigned treatment. Specifically, principal compliance
equals observed compliance for cases in the treatment group, since by assumption all individuals
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would comply with the control treatment. For cases in the control group observed compliance is
always one, but principal compliance is unobserved, since we do not know if individuals would
have complied if they had been assigned the active treatment. The key feature of principal
compliance is that, unlike observed compliance, it is not affected by the treatment assigned, and
hence can be used as a stratification variable in treatment comparisons, if the missing data
problem can be solved.
As discussed in Section 6, our analysis extends readily to the case where there is a third
group, always-takers, who take the active treatment whether or not assigned to the control or
active treatment. For the moment we assume there are no always takers, as would be the case if
individuals assigned to the control treatment cannot obtain access to the active treatment.
An intention-to-treat (IT) analysis in this setting computes and compares the average
outcome in the treatment and control groups, ignoring information on compliance. The IT
analysis is protected from selection bias by the randomization, and it measures treatment
effectiveness, which is the effect of assigning the treatment without regard to whether or not the
treatment is in fact taken. However, the IT analysis arguably does not provide a satisfactory
estimate of efficacy, that is, the effect of the treatment itself, since treatment non-compliers are
counted as treated cases even though they never received the treatment. We focus here on other
approaches that use compliance information to estimate treatment efficacy.
Two simple and widely- used approaches to treatment efficacy are as-treated analysis
(AT), where individuals are classified according to the treatment they actually received; that is,
treatment non-compliers are included in the placebo group; and per-protocol analysis (PP),
where only individuals who comply with the assigned treatment are included in the treatment
comparison; that is, treatment non-compliers are excluded from the analysis. As noted in the
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introduction, both of these analyses are subject to selection bias; for example in the case of PP
analysis, compliers to the control treatment (by assumption, the entire population) may differ
systematically from compliers to the active treatment, so the populations being compared are not
comparable. An alternative approach known as instrumental variable estimation (IV) has been
suggested, namely the IT estimate (the difference in means for treatment and control ignoring
compliance) divided by the proportion of compliers in the treatment group (Bloom 1984;
Newcombe, 1988; Robins 1989; Sommer and Zeger 1991; Baker and Lindeman, 1994; Angrist,
Imbens and Rubin, 1996, henceforth denoted as AIR). As shown in the next section, the IV
estimator is not subject to the selection bias noted for the AT and PP estimates, although it does
require assumptions to be valid.
Since AT, PP and IV are all estimates of treatment efficacy, it is important to define
precisely what we mean by that term. Two strands of the literature can be distinguished. One
focuses on the complier-average causal effect (CACE), which is the average treatment effect in
the subpopulation of principal compliers, for which C = 1 (AIR). An alternative estimand is the
average treatment effect (ATE), which is defined as the difference in mean outcome if all
individuals had been assigned and complied with the treatment and the mean if all individuals
had received the control treatment. The ATE requires that it is reasonable to consider the
treatment outcome for non-compliers, in the counterfactual event that they had complied with the
treatment. It is somewhat controversial whether this counterfactual event is useful to
contemplate, and arguably this varies according to context. For example, noncompliance to a
behavioral treatment such as an exercise regime might plausibly be changed by increased
motivation, as might occur if evidence that the treatment is successful becomes widely known.
On the other hand, if noncompliance to a drug is the result of intolerable side-effects, then
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compliance may require a reformulation of the drug to remove the side effects. Arguably this
may change the properties of the drug, and estimation of the ATE is consequently more
speculative.
The distinction between the CACE and the ATE is not a major issue in our simple
setting, since in the absence of covariates, the ATE and CACE reduce to the same estimand
under the assumption that the average outcome under the treatment is the same for compliers as
for non-compliers if they had in fact complied. In situations where this assumption does not hold,
the ATE and CACE differ, but additional information than that assumed here is needed to
estimate the difference.
In the case where covariate information is available, the usual additional assumption to
identify the ATE is that the average outcome under the treatment is the same for compliers and
non-compliers within strata defined by the covariates. The CACE and ATE are then the same
within strata, but the overall CACE and overall ATE differ in how the stratum-specific estimates
are weighted when combining over strata; specifically for the CACE the natural choice is to
weight using the covariate distribution of compliers, whereas for the ATE the natural choice is to
weight using the covariate distribution of compliers and non-compliers. This difference in
weighting is only important if the covariates modify the effect of the treatment and are related to
compliance, and we think it is likely to be minor in many applications. We focus on the CACE in
the sequel, in order to avoid the need for assumptions about counterfactual conditions.
In the next section we introduce notation that allows us to define the PP, AT and IV
estimators explicitly, and clarify the assumptions under which they yield consistent estimates of
treatment efficacy. In Section 5 we consider the precisio n of the three estimates, and implications
for allocation of the sample between the treatment and control group. In Section 6 we consider
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extensions of the methods to include observed covariates are then discussed, emphasizing the
contrasting role of covariates. Finally in Section 7 we discuss briefly generalizations of the
problem considered here and make some closing remarks.
4. The AT, PP and IV Estimators and When they are Consistent for the CACE
Let R denote the indicator for the random treatment assignment, with value 1 if an
individual is assigned to treatment and 0 if assigned to control. Note that in our notation R is the
treatment randomized, and T is the treatment received, so for non-compliers assigned the active
treatment R = 1 but T = 0. Let C be the indicator for principal compliance, with value 1 for
individuals who comply with the treatment if assigned, and 0 otherwise. We make the stable
unit-treatment value assumption (SUTVA) (Rubin, 1978), which implies that compliance and
outcomes for individuals are not affected by the assignments and outcomes of other individuals
in the sample (AIR). Table 1A shows a classification of the population by R and C, assuming a
proportion α of the population is assigned to the population and a proportion β are principal
compliers. The entries reflect the fact that R and C are independent, which is justified under the
assumption that treatments are randomly assigned. The proportions in square parentheses are
unobserved for the sample, since the principal compliance status of individuals in the control
group is unknown – we do not know whether they would have complied with the active
treatment if assigned to that treatment.
We now introduce an outcome variable Y, and let µrc denote the mean of Y for the
subpopulation with R = r and C = c; let yrc denote the corresponding sample mean, and nrc the
corresponding sample size. The populatio n means are displayed in Table 1B, with square
parentheses indicating quantities for which the corresponding sample estimates are not observed.
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The observed sample counts and means are shown in Table 1C. The CACE is then the difference
in complier means, δ = µ11 − µ01 .
If principal compliance were known for all individuals in the sample, a direct estimate of
the CACE would be y11 − y 01 . However, in practice the means in the four cells of Table 1B are
not observed, and additional assumptions are needed to yield a CACE estimate.
One possibility is to assume
NCEC: µ00 = µ01 ,

(1)

which asserts that the mean outcome in the control group is the same for principal compliers and
never-takers. We label this assumption “no compliance effect for controls” (NCEC). Condition
(1) is implied by the following conditional independence assumption:
NCEC*: [Y ∧ C | R = 0] ,

(2)

where the symbol ∧ denotes independence. Under NCEC or NCEC*, it is natural to estimate
both µ00 and µ01 by the marginal control mean y0+ , leading to the PP estimate of the CACE:

δˆPP = y11 − y0+ ,

(3)

which includes cases that take their assigned treatments. The problem with this estimator is that
the NCEC assumption is generally considered questionable, since compliers and non-compliers
may differ on various unobserved characteristics related to the outcome under the control
treatment. NCEC can be weakened by adjusting for known covariates that characterize
differences between compliers and never-takers, as discussed Section 5.
Note that participants in the subpopulation of never-takers (C = 0) are randomly assigned
to treatment or control, and in both cases they receive the same (control) treatment. Thus it is
often reasonable to assume the means in the first column of Table 1B are equal, that is:
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ER: µ 00 = µ10 .

(4)

This assumption is often called the exclusion restriction (ER) in the literature, a term that
originates in the econometric literature (see e.g. AIR). The ER assumption is implied by the
following conditional independence assumption:
ER*: [Y ∧ R | C = 0] .

(5)

ER or ER*, though often plausible, are assumptions, since the outcome may be affected by
whether treatment or control is assigned even though the resulting treatment remains the same,
particularly in trials of behavioral interventions. Under ER or ER*, it is natural to estimate both
µ00 and µ10 by y10 . The estimate of µ01 that yields the marginal mean y0+ when averaged with
y10 is
µˆ 01 = ( n0+ y0+ − n00 y10 ) / n01 ,

(6)

but this cannot be computed since n00 and n01 are unobserved. However, the principal
compliance rate for controls n01 / n0+ can be estimated by the principal compliance rate for cases,
n11 / n1+ , since the underlying population rates are the same by randomization. Replacing n01 / n0+
by n11 / n1+ in (6) yields µˆ 01 = ( n1+ y0+ − n10 y10 ) / n11 , and the following IV estimate of the CACE:

δˆIV = ( y11 − µˆ 01 ) = ( y1+ − y0+ ) / βˆ ,

(7)

the intention to treat estimator divided by βˆ = n11 / n1+ , the compliance rate for cases. The
estimator (7) is commonly termed the instrumental variable (IV) estimate, since it is a special
case of IV estimation with the randomization indicator as the instrument.
Suppose now we assume NCEC and ER simultaneously:
NCEC + ER: µ 00 = µ 01 = µ10 ,

(8)
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or the corresponding conditional independence assumptions NCEC*+ER*. The natural estimate
of the control mean is y0 = ( n0+ y0+ + n10 y10 )/(n 0+ + n10 ) , pooling the data in the three cells that
receive the control treatment T = 0. The resulting estimate of the CACE is AT estimate

δˆAT = y11 − y0 ,

(9)

which classifies all cases according to the treatment they received.
To summarize, the NCEC assumption leads to δˆPP , the ER assumption leads to δˆIV and
the NCEC and ER assumptions combined lead to δˆAT . The choice between the estimators rests
largely on the perceived validity of their underlying assumptions, although the precision of the
estimates may also play a role.
5. The Precision of the Alternative Estimators, and Design Implications
5.1. Comparison of the AT, PP and IV Estimators
For simplicity, we assume that the within-cell variance of Y in each of the cells in Table 1
is σ 2 ; also since the ER assumption is often plausible, we compare biases and variances of the
estimates under that assumption. Under these conditions, the large-sample biases of the ER, PP
and AT estimates are

B(δˆIV ) = 0 ,

(10)

B(δˆPP ) = (1 −β ) ∆σ ,

(11)

1− β
B(δˆAT ) =
∆σ ,
1 − αβ

(12)

where ∆ = ( µ 01 − µ00 ) / σ , which is zero under the NCEC assumption. The large sample variances
of the three estimators are

Var (δˆIV ) =

σ2
1 + β (1 − β )∆ 2 ) ,
2 (
nα (1 − α ) β

(13)
12
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Var (δˆPP ) =
σ
Var (δˆAT ) =
n

2

σ2
(αβ + 1 − α + αβ 2 (1 − β ) ∆ 2 ) ,
nα (1 − α ) β

(14)

 1
1 (1 − α ) β (1 − β )∆ 2

+
+
1 − 2αβ + αβ 2 )  ,
(

4
(1 − αβ )
 1 − αβ αβ


(15)

2
2
. It can be shown with some algebra that σ IV2 ≥ σ PP
≥ σ AT
.

IV is markedly less efficient than PP and AT for small values of β . This is illustrated in
Figure 1, which plots the asymptotic relative efficiencies Var (δˆPP ) / Var (δˆIV ) and

Var (δˆ AT ) / Var (δˆIV ) of IV compared to PP and AT against β , when µ00 = µ10 = 0 , µ11 = 2 ,
σ 2 = 1 , α = 0.5 . Figures 2 and 3 show the mean squared error (MSE = B 2 (δˆ ) + Var (δˆ) ) of the

three estimators for various choices of α , β and ∆ , which are measured in units of σ 2 n . If we
assume both ER and NCEC, that is, ∆ = 0 , δˆAT is preferred to δˆIV . If we assume ER but do not
assume NCEC, that is, ∆ ≠ 0 , δˆAT might still be preferred to δˆIV , if the bias is small and
compensated by a large reduction in variance. (For given bias, bias increasingly dominates
variance as the sample size increases, so in large samples δˆIV is preferred to both δˆAT and δˆPP .)
If one of either NCEC or ER is assumed true, the other assumption can be tested
empirically by comparing y10 − y 0+ with zero; since IV and AT both assume ER, one might
increase the efficiency of the CACE estimate by choosing AT over IV if this test is not rejected,
or the difference y10 − y 0+ is “small”. This approach has most appeal when the compliance rate is
low, since in this case δˆIV has substantially higher variance and the power of the test may be
reasonable; when compliance is high the power of the test is very modest. An indirect approach
to checking the ER assumption using covariates is discussed in Section 6 below.
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What fraction α of cases should be assigned to the treatment group for optimal
efficiency? Differentiating (13) with respect to α , the variance of the IV estimate is minimized
when α = 0.5 , that is, an equal allocation of treated and control cases. One might think that
given noncompliance, more cases should be assigned to the treatment group, but an equal
allocation is optimal for the IV estimator under our variance assumptions. On the other hand, the

)

(

variance of the per-protocol estimate is minimized when α = α PP = 1/ 1 + β (1 + ∆2 β (1 − β ) .

(

)

When ∆ = 0 , α PP = 1/ 1 + β , which does assign more cases to the treatment group when there
is noncompliance.
5.2 CACE Estimates for the Women Take Pride Study
We illustrate the AP, PP and IV estimates with data from the Women Take Pride (WTP)
study. As discussed in Section 2, we restrict attention to randomized subjects, and compare
women assigned to Group behavioral intervention (R =1) with the Control “usual care” treatment
(R =0).
Table 2 shows the observed counts and means for the outcome “6 minute walk” taken at
month 12, measuring the distance in feet an individual can walk in 6 minutes. These analyses
exclude 69 of the 190 cases in the intervention group and 62 cases in the control group who drop
out before month 12. For the current analysis we assume that drop out is random within each
treatment group – the analysis in Section 7.2 relaxes this assumption by allowing dependence of
the dropout on baseline covariates. In the treatment group βˆ = 105/121 =86% complied with
treatment, where compliance is defined here as completion of at least one of the treatment
modules. Table 2 also shows the estimated cell means from the (a) PP, (b) IV and (c) AT
methods; the estimated means in italics are equated because of the model assumptions. For
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example, the mean for compliers in the control group equals the mean for compliers in the
treatment group by ER, and is estimated to be 694.12; the mean for compliers in the control
group equals the mean for non-compliers in the control group by NCEC and is estimated to be
748.90. The last row of the lower panel of Table 2 shows the corresponding estimates of the
CACE, and associated standard errors, computed using Eqs. (13)-(15). Note that the estimates of
the CACE from the three methods are somewhat different, and the PP and AT estimates are
statistically significant at the 0.05 alpha level. The standard errors are ordered as described
above, with relative small differences since the compliance rate is quite high in this application.
The t-test for the combined NCEC + ER assumptions compares the mean for controls (748.90)
with the mean for treatment non-compliers (694.12), statistically not significant even though the
difference in means is quite substantial. This illustrates the low power of the test when the
compliance rate is high.
6. Model-Based Estimation
We have noted that the potentially high variance of the IV estimator when the compliance
rate is low. The precision of δˆIV can be improved by seeking a more efficient estimator.
Technically all the estimators considered so far can be viewed as method-of- moment estimators
under the various assumptions. Another approach to inference is maximum likelihood (ML)
estimation based on a model for the joint distribution of Y, R and C. In particular, suppose Y
given R, C is assumed normal with mean µ rc and variance σ 2 . The loglikelihood of the
observed data, assuming independent observations, is:

(

)

l {µ rc }, β , σ 2 | data = −0.5n log σ 2 − ∑ i:r =1 0.5( yi − µ1, c ) 2 / σ 2

(

i

i

)

(

)

+ ∑ i:r = 0 log π i exp −0.5( yi − µ 01) 2 / σ 2 + (1 − π i )exp −0.5( yi − µ 00 ) 2 / σ 2 ,
i
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where π i is the compliance rate for subject i, and is assumed equal to β with no covariates.
Without constraints on {µ cr } , the means in this loglikelihood are not identified, but they are
identified under the ER and/or NCEC assumptions. It is easily shown that δˆPP is ML for this
model under the NCEC assumption (1), and δˆAT is ML under the NCEC and ER assumptions
(8). However δˆIV is not the ML estimate under the ER assumption (4). The ML estimate (say

δˆMLER ) does not have an explicit form, but is quite easily computed using the EM algorithm,
treating the compliance indicators for the controls as missing data (AIR).
The estimate δˆMLER is more efficient than δˆIV (Imbens and Rubin 1996), but makes
stronger distributional assumptions; in particular, we conjecture that it is sensitive to violations
of the assumption of a constant variance for compliers and non-compliers when R =0. While

δˆMLER and δˆIV differ under the normal model, the ML estimate equals δˆIV for binary outcomes Y
with a Bernoulli distribution, providing the resulting means in Table 1B, which are estimated
probabilities for a binary Y, all lie between zero and one (Baker and Lindeman 1994).
7. Methods That Include Covariate Information
7.1. CACE Estimation with Covariates.
We now consider how covariates X measured for compliers and non-compliers can be
used to improve the performance of the AT, PP and IV estimates. Related questions are the
properties of a good covariate, and approaches to dimension reduction when a large number of
covariates are available.
For AT and PP, the covariates can be adjusted by a regression model of Y on X and a
dummy variable T for the received treatment. All cases are included for AT analyses, and noncompliers assigned the treatment are excluded for PP analysis. As in covariate adjustments in
16
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observational settings, inclusion of X can reduce selection bias from noncompliance and increase
precision. Concerning bias, a correctly-specified regression adjustment with covariates X
weakens NCEC* in (2) to
NCEC*( X ): [Y ∧ C | X , R = 0] ,

(16)

that is, to an assumption that there is no compliance effect for controls within strata defined by X.
Covariates that are predictive of the outcome can also increase precision by reducing the residual
variance σ 2 of the regression of Y on X and T.
A strategy for robust modeling when there are a number of covariates is to stratify on a
coarsened function c ( X ) of the covariates X. To limit bias, a function is sought such that if (16)
is true, then it remains valid with X replaced by c ( X ) . A standard application of the propensity
score theory of Rosenbaum and Rubin (1983) implies that the coarsest function c ( X ) with this
property is the propensity to comply, p ( X ) = p(C = 1 | X ) . This score can be estimated by
regressing the compliance indicator C on the covariates using the cases assigned to treatment;
control cases are excluded since C is not known for them. Note that the same propensity score
applies for both AT and PP, because the NCEC assumption is shared by both methods. AT also
requires the ER assumption, but that is not addressed by the propensity adjustment.
Covariates do not play a role in bias reduction for the IV method. To see this, suppose
ER* is assumed conditional on X, that is
ER*(X ): [Y ∧ R | X , C = 0] .

Then in terms of densities,
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p (Y | R = 1, C = 0) = ∫ p (Y | X , R = 1, C = 0) p ( X | R = 1, C = 0) dX
= ∫ p (Y | X , R = 0, C = 0) p ( X | R = 1, C = 0) dX
= ∫ p (Y | X , R = 0, C = 0) p ( X | R = 0, C = 0)dX
= p (Y | R = 0, C = 0),

where the first and last equalities are by definition, the second is implied by ER*(X), and the
third equality is true by the randomization of treatments. Thus ER*(X) implies ER*, so the latter
is not weakened by conditioning on X, and the covariates do not play a role in bias reduction.
Covariates can be used to increase the precision of δˆIV , however. We first consider the
modification of δˆIV for a single categorical X with J categories. Denote the IV estimator within
the stratum X = j as δˆIV , j = ( y1 + j − y0 + j ) / βˆ j , with the subscript j denoting stratum. Let p j be
the proportion of cases in stratum j, estimated from the pooled sample. Then p j βˆ j / ∑ k =1 pk βˆk
J

estimates the proportion of compliers in stratum j. Weighting δˆIV , j by this proportion and
summing over strata yields the stratified IV estimator
J
J
δˆI V|X = ∑ j =1 p j ( y1+ j − y0+ j ) / ∑ j=1 p j βˆ j .

(17)

The numerator of y I V| X is a stratified form of the IT estimator, and its precision is improved by
stratifying on covariates that are predictive of the outcome. The denominator of y I V| X is a
stratified estimator of the overall compliance rate, and its precision is improved by stratifying on
the covariates that are predictive of compliance. We conjecture that the former of these two
components has the greater potential for variance reduction. A natural generalization of y I V| X for
a set of categorical and/or continuous X’s is
δˆI V|X = ∑ i ( yˆ1i − yˆ 0i ) / ∑ i βˆi ,

(18)
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where the summation is over all individuals i in the samp le; yˆ ri is the predicted outcome for unit
i if randomized to treatment r, computed from a regression of Y on X and R; and βˆ i is the
predicted true compliance for unit i, computed from a regression of C on X estimated from the
cases assigned to treatment. The latter should be of a form appropriate for a binary outcome, for
example logistic or probit regression. We are not aware of discussions of (17) or (18) in the
compliance literature.
An alternative to (17) or (18) is to compute ML or Bayes estimates of the CACE given
covariates X, using a full model for the distribution of Y and C, given R and X, and treating the
compliance indicators in the control group as missing covariates (Imbens and Rubin, 1997a;
Little and Yau 1998). The model can be specified in terms of a compliance model for C given R
and X indexed by parameters θ C , and an outcome model for Y given C, R and X indexed by
parameters θ Y . The loglikelihood takes the form

l(Y , Cobs | R, X Y , X C ;θ Y ,θ C ) =

∑ ( log ( f (Y
Ri =1

+

i

∑  log (π ( X

Ri = 0

i

)

(

)

| Ri , X Yi , Ci ;θY ) + C i log π i ( XC i ;θ C ) + (1 − C i )log (1 − π i( X Ci; θ C )
Ci

(

)

(19)

)

)

;θ C ) f (Yi | Ri , XYi , Ci = 1; θY ) + 1 − π i( XC i ; θC ) f ( Yi | Ri , XYi , Ci = 0);θ Y 


In these models, the compliance model should exclude the main effect of R and interactions
including R, because of the assumption of randomization of treatments. The outcome model
should exclude effects of the form RU, where U is the identity or a set of some or all the
covariates, because these effects concern the effects of compliance for controls, which are
assumed zero under ER. The modeling approach yields gains of efficiency over the IV approach
(Imbens and Rubin 1997a, 1997b), but may be more vulnerable to model misspecification; more
simulations comparing the methods would be of interest.
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We noted in Section 4 that the data do not provide evidence of the validity of ER or
NCEC. With covariates, the same comment applies within strata defined by the covariates.
However, if the covariates are good predictors of compliance, the relationship between outcome
and predicted compliance can be assessed in the control group, and lack of evidence of a
relationship might be construed as indirect evidence in favor of the NCEC assumption.
Specifically, transform the covariates X into the propensity score pˆ ( X ) and covariates Z
orthogonal to pˆ ( X ) , and regress Y on pˆ ( X ) and Z in the control group. If the coefficient of
pˆ ( X ) in this regression is small, this provides some justification for the NCEC assumption,

suggesting that PP or AT analysis may be reasonable options. On the other hand if the regression
coefficient of pˆ ( X ) is large, estimates like δˆIV or δˆMLER that do not require the NCEC
assumption may be preferable.
7.2 Women Take Pride Data Analysis with Covariates
We now extend our analyses in Section 5.2 to include adjustment for baseline covariates.
We considered, in addition to 6- minute walk at baseline, the covariates previously included in
Janevic, et al. ( 2003), including age, employment and Symptom Impact Profile (SIP) physical
score, which measures a subject’s physical functioning. The ML estimate of the CACE for the
data without adjusting for covariates is δˆMLER = 109.78 , close to the IV estimate of δˆIV = 108.76
in Table 2. It has a slightly lower standard error (61.28 vs. 65.53). Table 3 shows the results of
fitting a model of form (19) to the data from the WTP study. Block (1) shows the coefficients for
the outcome model, with the CACE being the Compliance*Treatment interaction. Block (2)
shows coefficients from the compliance model. The covariate-adjusted the ML estimate of the
CACE from this model is 97.20 with a reduced standard error, namely 43.73, indicating some
improvement in precision from adjusting for the covariates. In addition, women with higher
20
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baseline measure tend to have higher 6- min walk measure at month 12, and older women tend to
have lower 6-min walk measure at month 12. Table 4 summarizes the IV, MLN-ER, PP and AT
estimates both with and without covariate adjustments. PP and AT estimates with covariate
adjustments are obtained using linear regression adjusting for age, baseline 6- minute walk
measurement, and employment status. Table 4 shows that covariate adjustment generally
improves precision and reduces differences between the methods. The large gain in efficiency
may be due to the significant effects of age and baseline measurements on the outcome of
interest. The results suggest that compliers performed better under treatment rather than under
control with respect to this outcome.
8. Discussion.
We have compared a variety of methods for estimating efficacy in randomized trials for a
control and active treatment, when there is all-or-nothing compliance in the treatment arm. This
work applies directly to two active treatments A and B, when compliance is perfect for treatment
A, and noncompliance to treatment B means taking treatment A. In practice, the choice of
methods depends on various factors, effect sizes relative to between-subject variability of the
outcome measure, sample size and differences in characteristics of compliers and non-compliers.
The choice also depends on the plausibility of the different modeling assumptions and the tradeoff between efficiency and robustness. If NCEC or NCEC+ER given a set of covariates can be
believed, and regressions on the covariates are correctly specified, then AT can be dramatically
more efficient than IV. On the other hand, the IV estimate of the CACE under ER is robust
against misspecification of our regression model or false belief in NCEC. Thus, it may be wise to
compute and compare all the estimates to assess sensitivity of answers to the choice of method.
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Many generalizations and extensions of these methods are possible. A relatively
straightforward generalization is to add to the never-takers (C =0) and compliers (C =1) a
subpopulation of always-takers (say C = 2), who obtain the active treatment whether assigned to
treatment or control. This adds an additional column to Table 1. The CACE is still defined as the
treatment effect in the subpopulation of compliers, the middle column of the tables, and a second
restriction on the means is required to identify the parameters. The PP estimate assumes
µ00 = µ01 (NCEC, as before) and also µ11 = µ12 , that is, the mean outcome under treatment is the
same for compliers and always takers. The ER assumption in IT analysis yields two restrictions,
µ00 = µ10 (as before) and µ02 = µ12 , that is, the treatment mean outcome for always-takers is the
same regardless of the treatment assigned). The AT analysis assumes µ00 = µ01 = µ10 and
µ11 = µ12 = µ02 , leading to pooling the means in the (00, 01, 10) and (11,12, 02) cells. The
propensity to comply discussed in Section 3 is replaced by two propensities,
Pr(C = 1| X , R = 1, C = 1 or 0) and Pr(C = 1| X , R = 0, C = 1 or 2) . An interesting new possibility

is hybrid models that mix the NCEC and ER assumptions. For example one might assume
µ00 = µ01 (NCEC) and µ20 = µ 21 (ER for always-takers only).
A further extension is to allow the possibility of “defiers” who take the opposite of the
treatment assigned (AIR). However this group requires additional assumptions to identify the
parameters, and since defiance is incompatible with a consistent preference for one or other of
the treatments, the assumption of “no defiers” is commonly made in practice.
Other extensions that require more restrictions to identify the parameters include the case
where partial compliance is modeled (Goetghebeur & Molenberghs 1996), or there are more than
two treatments, such as two active treatments and a control treatment that is assumed to apply to
non-compliers. CACE estimation in trials involving a control group and more than one treatment
22
http://biostats.bepress.com/harvardbiostat/paper84

groups is more complicated, and consists of more principal compliance categories and involves
more complicated identifiability assumptions. The results will be reported elsewhere.
Another extension is to consider joint models for noncompliance and missing data – for
simplicity we confined our analyses of 12 month WTP data to completers. For some approaches
to this issue see Frangakis and Rubin (1999) and Peng, Little and Raghunathan (2004).
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Table 1. Classifications by Treatment and Principle Compliance: (A) Population
Proportions; (B) Population Mean Outcomes; (C) Observed Means (Sample Counts).
A

Randomized
Treatment R

0
1
ALL

Compliance C
0
1
[(1 − α )(1 − β )] [(1 − α ) β ]
α (1 − β )
αβ
[1 − β ]
[β ]

0

Compliance C
0
1
[ µ 00 ]
[ µ 01 ]

ALL
1−α
α

[] = not observed
B

Randomized
Treatment R

1

µ10
[ µ +0 ]

µ11
[ µ +1 ]

µ0+
µ1+

[] = not directly estimable without assumptions
C.

Randomized
Treatment R

0
1

Compliance C
0
1
?
?
y10 ( n10 )
?

y11 ( n11 )
?

y0+ ( n0+ )
y1+ (n1+ )
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Table 2. Women Take Pride Study: (A) Sample Means (Sample sizes) for Outcome 6
Minute Walk in Control and Group Tre atment Subgroups, and (B) Predicted Means under
PP, IV and AT Models.
A

Randomized
Treatment R

0
1

Compliance C
0
1
?
?
694.12 (16) 866.01 (105)

748.90 (122)
843.28 (121)

B
Treatment R

IV

PP

AT

0
1
CACE
(SE)

Compliance
Compliance
Compliance
0
1
0
1
0
1
694.12
757.25 748.90
748.90
742.55
742.55
694.12
866.01 694.12
866.01
742.55
866.01
108.76
117.11
123.45
(65.53)
(58.97)
(57.37)
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Table 3. Women Take Pride Study: ML estimates of Regression Coefficients of Models for
the Outcome 6-Min Walk and Compliance with Covariates

Parameter

Estimate (B) SE(B)
Outcome Model (1)
707.97
278.89
-6.763
3.404

Intercept
Age

Baseline 6- min Walk
Employment
Treatment Compliance
Compliance *Treatment

Intercept
Employment

< 0.001
0.032

0.048
55.18
84.87
43.73

< 0.001
0.59
0.83
0.043

Compliance Model (2)
2.259
0.497
-0.464
0.792

< 0.001
0.526

Baseline SIP Physical

0.707
28.71
-29.72
97.20

P-Value

-0.040

0.041

0.282

Table 4. Women Take Pride Study: IV, MLN-ER, PP and AT estimates for the Outcome 6Min Walk, with and without covariate adjustment

Covariates
Unadjusted

Adjusted

Estimate
SE

IV
108.76
65.53

MLN-ER
109.78
61.28

PP
117.11
58.97

AT
123.45
57.37

Estimate
SE

100.05*
44.25*

97.20
43.73

95.58
40.30

90.13
38.74

* Estimate is computed using formula (18) and its SE is computed using the bootstrap
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Figure 1. Asymptotic Relative Efficiency of IV compared to PP and AT.
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Figure 2. MSE of Estimates for varying population propo rtions in the treatment arm, α ,
when compliance rate , β =0.751, n=575 and treatment effect size n ∆ =0,5,10 clockwise
for three graphs, respectively.
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Figure 3. MSE of Estimates for varying compliance rate, β , when the population
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Appendix: Large sample variances of IV, PP and AT
All the estimates are of the form g ( y10 , y11 , y0 + , βˆ) , where ( y10 , y11, y0+ , βˆ ) are asymptotically
independent with variances

Var ( y10 ) =

σ2
,
nα (1 − β )

Var ( y11 ) =

σ2
,
nαβ

σ 2 (1 + ∆ 2 β (1 − β ))
,
n(1 − α )
β (1 − β )
Var ( βˆ ) =
nα
Var ( y0 + ) =

2

2

2

 ∂g 
 ∂g 
 ∂g 
 ∂g 
ˆ
Hence Var ( g ) = 
 Var ( y10 ) + 
 Var ( y11 ) + 
 Var ( y0+ ) + 
 Var ( β )
∂
y
∂
y
∂
y
∂
β


 10 
 11 
 0+ 
2

(A) δˆIV = y11 + y10 (1 − βˆ ) / βˆ − y0+ / βˆ

 ∂g  ˆ −1
 ∂g 
 ∂g 
µ10 − µ0+ βˆ∆σ
−1  ∂g 
=

 = β − 1, 
 = 1, 
 = − βˆ ,  ˆ  =
βˆ 2
βˆ 2
 ∂y11 
 ∂y10 
 ∂y0+ 
 ∂β 
σ 2  (1 − β ) 2
1
12 1 + ∆2 β (1 − β ) ∆2 β (1 − β ) 
ˆ
Var (δ IV ) =
+
+
+

n  β 2 α (1 − β ) αβ
β 2 (1 − α )
β 2α

2
2 2
σ
∆ σ (1 − β )
So =
[ (1 − β )(1 − α ) + β (1 − α ) + α ] +
[α + (1 − α ) ]
2
n β α (1 − α )
nβα (1 − α )
=

σ2
1 + ∆ 2β (1 − β ) 
2
n β α (1 − α )

(B) δˆPP = y11 − y0+

 ∂g 
 ∂g

 = 1, 
 ∂y11 
 ∂y0+


σ 2  1 1 + ∆ 2β (1 − β ) 
ˆ
=
−
1
So
Var
(
δ
)
=

PP
 αβ +

n
(1 − α )
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(1 − α ) y0+ + α (1 − βˆ ) y10
α (1 − βˆ )( y10 − y0 + )
(C) δˆAT = y11 −
= y11 − y 0+ +
1 − αβˆ
1 − αβˆ

 ∂g  α (1 − βˆ )  ∂g 
 ∂g
,
= 1, 

=

 ∂y10  1 − αβˆ  ∂y11 
 ∂y0 +

 1 − α  ∂g  −∆βσα (1 − α )
,
=
=
(1 − αβˆ) 2
 1 − αβˆ  ∂βˆ 

So
2
2
2
2
2
2 2 2
2
σ  α (1 − βˆ )
1
1
(1 − α ) 1 + ∆ β (1 − β ) β ∆ α (1 − α) β (1 − β ) 
Var (δˆAT ) =
+
+
+


4
n  (1 − αβˆ ) 2 α (1 − β ) αβ (1 − αβˆ ) 2
(1 − α )
α
(1 − αβˆ )

2
2 2
ˆ
σ  α (1 − β )
1
(1 − α )  σ ∆ β(1 − β )(1 − α )
 (1 − αβˆ ) 2 + α (1 − α ) βˆ 2 
=
+
+
+

2
2
4


ˆ
ˆ
ˆ
n  (1 − αβ ) αβ (1 − αβ ) 
n(1 − αβ )

=

2
2 2
σ  1
1  σ ∆ β(1 − β )(1 − α )
1 − 2αβˆ + αβˆ 2 
+
+


4


ˆ
ˆ
n  (1 − αβ ) αβ 
n(1 − αβ )
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